Rationale and Study Design of the Adaptive Study of IL-2 Dose on Regulatory T Cells in Type 1 Diabetes (DILT1D): A Non-Randomised, Open Label, Adaptive Dose Finding Trial
BMJ Open - United Kingdom
doi 10.1136/bmjopen-2014-005559
Full Text
Open PDFAbstract
Available in full text
Categories
Date
June 4, 2014
Authors
Publisher
BMJ